<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287092</url>
  </required_header>
  <id_info>
    <org_study_id>A5I15</org_study_id>
    <nct_id>NCT00287092</nct_id>
  </id_info>
  <brief_title>Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants</brief_title>
  <official_title>A Randomised, Controlled, Double-Blind Study of the Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed) Compared To Infanrix®-IPV+Hib When Both Vaccines Are Given to Infants Using a Three Dose Immunisation Schedule (&quot;Nordic Schedule&quot; 3-5-12 Months)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Pediacel™ is currently licensed in the UK for use as a 3 dose regimen for the active
      immunisation of infants against Diphtheria, Tetanus, Pertussis, Poliomyelitis and invasive
      infections caused by Haemophilus influenzae type b. However there are currently no clinical
      data supporting the use of Pediacel™ using a 3, 5, and 12 months of age vaccination schedule.
      This study is designed to provide safety and immunogenicity data to support the use of
      Pediacel™ according to a 3, 5, and 12 months schedule.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the immunogenicity of PEDIACEL® Vaccine.</measure>
    <time_frame>1 Month post-dose 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To provide information concerning the safety after administration of PEDIACEL® Vaccine</measure>
    <time_frame>Entire study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">807</enrollment>
  <condition>Pertussis</condition>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Poliomyelitis</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive PEDIACEL vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive Infanrix-IPV+Hib vaccines</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DT5aP-IPV-Hib 5-component Pertussis vaccine</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Pediacel™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix® -IPV+Hib</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Infanrix®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants aged 80 to 120 days inclusive on the day of inclusion.

          -  Born at full term of pregnancy (&gt; 37 weeks)

          -  Informed consent form signed by the parent(s) or other legal representative according
             to local regulations

          -  Parent(s) or legal representative able to attend all scheduled visits and to
             understand and comply with the study procedures (able to read and write; access to a
             telephone).

        Exclusion Criteria:

          -  Rectal temperature ≥ 38.0°C

          -  Moderate or severe acute illness with or without fever

          -  Participation in another clinical trial in the 4 weeks preceding the first trial
             vaccination

          -  Having received any DTaP, IPV, or Hib vaccines prior to study initiation or any
             vaccination in the 4 weeks preceding the first trial vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Known history of diphtheria, tetanus, pertussis, H. influenzae type b infections,
             poliomyelitis

          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term
             systemic corticosteroids therapy

          -  Systemic hypersensitivity to any of the vaccine components (including neomycin,
             streptomycin, polymyxin B and formaldehyde)

          -  History of a life-threatening reaction (such as encephalopathy, Hypotonic
             Hyporesponsive Episode, severe fever, convulsions, etc.) to the trial vaccine or a
             vaccine containing the same substances

          -  Blood or blood-derived products (immunoglobulins) received in the past 4 weeks

          -  Vaccination planned in the 6 weeks following any trial vaccination

          -  Known HIV seropositivity

          -  Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination

          -  History of seizures or progressive, evolving or unstable neurological condition

          -  Clinically significant findings on review of systems that might interfere with correct
             vaccination or which, in the opinion of the Investigator, would interfere with the
             evaluation of the vaccine or pose a health risk to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Days</minimum_age>
    <maximum_age>120 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Espoo</city>
        <zip>02100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jyvaskyla</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kotka</city>
        <zip>48100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lahti</city>
        <zip>15140</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pori</city>
        <zip>28120</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vantaa</city>
        <zip>01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vantaa</city>
        <zip>01600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostersund</city>
        <zip>S-831 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2006</study_first_submitted>
  <study_first_submitted_qc>February 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2006</study_first_posted>
  <last_update_submitted>January 6, 2015</last_update_submitted>
  <last_update_submitted_qc>January 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilus influenzae type b;</keyword>
  <keyword>Corynebacterium diphtheriae;</keyword>
  <keyword>Clostridium tetani;</keyword>
  <keyword>Bordetella pertussis;</keyword>
  <keyword>poliovirus types 1, 2 and 3;</keyword>
  <keyword>Vero cell;</keyword>
  <keyword>Influenza;</keyword>
  <keyword>Diphtheria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Tetany</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

